Dr Reddys unveils generic Deferasirox Tablets in US

The two different products launched by Dr Reddy's Labs in the US market are generic versions of Exjade (deferasirox) and Jadenu (deferasirox) indicated to treat iron overload caused by blood transfusions in adults and children at least 2 years old.

New Delhi: Hyderabad-based Dr Reddys Laboratories (Dr Reddys) recently announced the launch of Deferasirox Tablets for Oral Suspension and Deferasirox Film-Coated Tablets in the US market.

Deferasirox Tablets for Oral Suspension is a therapeutically equivalent generic version of Exjade (deferasirox) Tablets for Oral Suspension, approved by the U. S. Food and Drug Administration (USFDA) while Deferasirox Film-Coated Tablets, 90 mg and 360 mg, a therapeutically equivalent generic version of Jadenu (deferasirox) Film-Coated Tablets, 90 mg, 180 mg, and 360 mg, approved by the US health regulator.

Deferasirox is used to treat iron overload caused by blood transfusions in adults and children at least 2 years old. Deferasirox is also used to treat chronic iron overload syndrome caused by a genetic blood disorder in adults and children who are at least 10 years old.

Also Read: Dr Reddys launches a generic version of Hemabate injection indicated for abortion in the US

The Exjade brand had the US sales of approximately $113 million MAT and Jadenu brand had US sales of approximately $470 million MAT for the most recent twelve months ending in September 2019 according to IQVIA Health.

Dr Reddys Deferasirox Tablets for Oral Suspension, are available in 125 mg, 250 mg, and 500 mg dosage strengths in bottle count sizes of 30 and Deferasirox Film-Coated Tablets are available in 90 mg and 360 mg dosage strengths in bottle count
sizes of 30.

Also Read: Dr Reddys unveils cancer drug Bortezomib in the US